Viral Hemorrhagic Fever

Article Sidebar

PDF
Published: Dec 25, 2023
DOI: https://doi.org/10.47191/ijpbms/v3-i12-05
Keywords:
Viral Hemorrhagic fever, Pathogenesis of viral hemorrhagic, C-Reactive protein, Interleukin.

Main Article Content

Hind T. Hamad
Department of Medical Laboratory Technologies, Al-Dour Technical Institute, Northern Technical University, Saladin, Iraq.
Yaseen K. Mohammed
General Directorate of Education-Balad Education Department, Saladin, Iraq.
Abeer Saleh Hasan
College of health and medical technique - Aldour- department of optic, Northern Technical University, Saladin, Iraq.

Abstract

Most viruses implicated in these diseases require vectors for transmission to humans, most are transmitted by arthropods or rodent-borne infections, and due to the zoonotic nature of these diseases, these diseases are generally confined to endemic areas where their hosts live. Symptoms of the hemorrhagic fever virus include fatigue, aches, cough, fever, shortness of breath, and eye redness. Given that viral genome detection is the best tool for diagnosis, however, blood sampling requires personal medical training and involves important risks for the patient as well as for personal healthcare. Sampling may therefore be by non-invasive methods (eg, saliva or urine), as well as multiplex PCR, lateral flow assays, and non-invasive sampling, including saliva and urine. It was found that there are many immune indicators related to the hemorrhagic fever virus, including protein C and D-dimer, which were found to increase when infected with hemorrhagic fever. As for inflammatory cytokines, they were found to play an important role in causing infection with the hemorrhagic fever virus, including interleukin 6, interferon gamma, as well as About tumor necrosis factor.

Article Details

How to Cite
Hind T. Hamad, Yaseen K. Mohammed, & Abeer Saleh Hasan. (2023). Viral Hemorrhagic Fever. International Journal of Pharmaceutical and Bio Medical Science, 3(12), 728–733. https://doi.org/10.47191/ijpbms/v3-i12-05
Issue
Vol. 3 No. 12 (2023): Volume 03 Issue 12 December 2023
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Ahmed, Tariq Younis, Al-Hilali Louay Abdel Ali. Biochemistry. The second part. University of Mosul; 2010.

II. Vignesh Mariappan, Pooja Pratheesh, Lokesh Shanmugam, S.R. Rao, Agieshkumar Balakrishna Pillai. Viral hemorrhagic fever: Molecular pathogenesis and current trends of disease management-an update. Current Research in Virological Science. 2, 2021, 100009.

III. Schnittler, H.-J., and Feldmann, H. Viral hemorrhagic fever--a vascular disease? Thromb. Haemost. 2003; 89: 967–972.

IV. Basler, C. F. Molecular pathogenesis of viral hemorrhagic fever. Semin. Immunopathol. 2017; 39:551–561.

V. Abir, M. H., Rahman, T., Das, A., Etu, S. N., Nafiz, I. H., Rakib, A., et al. Pathogenicity and virulence of Marburg virus. Virulence. 2022; 13, 609–633.

VI. Hickman, M. R., Saunders, D. L., Bigger, C. A., Kane, C. D., and Iversen, P. L. The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections. PLoS Negl. Trop. Dis. 2022. 16:e0010220. doi: 10.1371/journal.pntd.0010220.

VII. Paessler, S., and Walker, D. H. Pathogenesis of the viral hemorrhagic fevers. Annu. Rev. Pathol. Mech. Dis. 2013; 8, 411–440.

VIII. Reynard, S., Russier, M., Fizet, A., Carnec, X., and Baize, S. Exonuclease domain of the Lassa Virus nucleoprotein is critical to avoid RIG-I signaling and to inhibit the innate immune response. J. Virol. 2014; 88, 13923–13927.

IX. Woolsey, C., Cross, R. W., Agans, K. N., Borisevich, V., Deer, D. J., Geisbert, J. B., et al. A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. PLoS Negl. Trop. Dis. 2022; 16:e0010433. doi: 10.1371/journal.pntd.0010433.

X. Lizdany Flórez-Álvarez ,Edmarcia Elisa de Souza , Viviane Fongaro Botosso , Danielle Bruna Leal de Oliveira .et al. Hemorrhagic fever viruses: Pathogenesis, therapeutics, and emerging and re-emerging potential. Institute of Biomedical Science. Volume 13 - 2022 | https://doi.org/10.3389/fmicb.2022.1040093

XI. Asogun DA, Günther S, Akpede GO, Ihekweazu C, Zumla A. Lassa Fever: Epidemiology, Clinical Features, Diagnosis, Management and Prevention. Infect Dis Clin North Am. 2019 Dec;33(4):933-951.

XII. Asogun DA, Günther S, Akpede GO, Ihekweazu C, Zumla A. Lassa Fever: Epidemiology, Clinical Features, Diagnosis, Management and Prevention. Infect Dis Clin North Am. 2019 Dec;33(4):933-951.

XIII. Drifa Belhadi, Majda El Baied, Guillaume Mulier, Denis Malvy, France Mentré, Cédric Laouénan .The number of cases, mortality and treatments of viral hemorrhagic fevers: A systematic review. Belhadi D, El Baied M, Mulier G, Malvy D, Mentré F, Laouénan C . The number of cases, mortality and treatments of viral hemorrhagic fevers: A systematic review. PLoS Negl Trop Dis . 2022; 16(10): e0010889. doi:10.1371/journal.pntd.0010889.

XIV. Asogun DA, Günther S, Akpede GO, Ihekweazu C, Zumla A. Lassa Fever: Epidemiology, Clinical Features, Diagnosis, Management and Prevention. Infect Dis Clin North Am. 2019 Dec;33(4):933-951.

XV. Bente DA, Forrester NL, Watts DM, McAuley AJ, Whitehouse CA, Bray M. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res. 2013 Oct;100(1):159-89.

XVI. Hidalgo J, Richards GA, Jiménez JIS, Baker T, Amin P. Viral hemorrhagic fever in the tropics: Report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine. J Crit Care. 2017 Dec;42:366-372.

XVII. Jung, J., Ko, S.-J., Oh, H. S., Moon, S. M., Song, J.-W., and Huh, K. Protective effectiveness of inactivated hantavirus vaccine against hemorrhagic fever with renal syndrome. J. Infect. Dis. 2018; 217, 1417–1420.

XVIII. Winkler, A. M., and Koepsell, S. A. The use of convalescent plasma to treat emerging infectious diseases. Curr. Opin. Hematol. 2015; 22, 521–526.

XIX. FDA (2022). FDA Approves First Treatment for Ebola Virus | FDA. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-ebola-virus [Accessed August 2, 2022].

XX. Luan YY, Yao YM. The clinical significance and potential role of C-reactive protein in chronic inflammatory and neurodegenerative diseases. Front Immunol .2018; 9: 1302–1308.

XXI. structure. Chemical structure of human c-reactive protein (crp). increased blood CanStock, canstockphoto,CRP. Available at: https://www.canstockphoto.com/human-c-reactive-protein-crp-chemical- 11386366.html (Accessed: 22 June 2021).

XXII. Büyüktuna SA, Doğan HO, Unlusavuran M, Bakir M. An evaluation of the different biomarkers to discriminate bleeding in Crimean-Congo Hemorrhagic Fever. Ticks Tick Borne Dis. 2019;10:997–1002.

XXIII. Querol-Ribelles JM, Tenias JM, Grau E, Querol-Borras JM, Climent JL, Gomez E, et al. Plasma d-dimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest. 2004;126: 1087–1092. pmid:15486368.

XXIV. Hadinegoro SRS. The revised WHO dengue case classification: Does the system need to be modified? Paediatr Int Child Health. 2012 May;32(Suppl 1):33–8.

XXV. Fagbami AH, Onoja AB. Dengue haemorrhagic fever: An emerging disease in Nigeria, West Africa. J Infect Public Health. 2018 Nov-Dec;11(6):757–762.

XXVI. Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clinical and Developmental immunology;2010.65.56789.

XXVII. Commins S.P, Borish L, Steinke J.W. "Immunologic messenger molecules : Cytokines , interferons , and chemokines", J. Allergy Clin . Immunol .2010; Vol . 125, PP. S53-S72 .

XXVIII. William B, Ershler MD. "interleukin-6 A cytokine for Gerontologists. Journal of the American Geriatrics society.2012; 41(2):176-181.

XXIX. Chareonsirisuthigul T, Kalayanarooj S, Ubol S. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J Gen Virol 2007; 88:365–375.